ReviewJournal of medicine and life
Cutaneous complications of molecular targeted therapy used in oncology.
Review in Journal of medicine and life. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 17 citations in OpenAlex.
- Systemic Steroid Treatment for Imatinib-Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study.The oncologist · 2020Trial
- Neutrophilic eccrine hidradenitis following dasatinib initiation in a patient with chronic myeloid leukemia.JAAD case reports · 2025Article
- Erythema nodosum following treatment with dasatinib plus chemotherapy in a patient with myeloid blast phase of chronic myeloid leukemia.Clinical case reports · 2023Article
- Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond.Endocrine reviews · 2019Review
- Antitumor pharmacotherapy of colorectal cancer in kidney transplant recipients.Therapeutic advances in medical oncology · 2019Review
- Cutaneous Toxicities of Molecular Targeted Therapies.Maedica · 2017Article
- Acute Paronychia and Reactive Capillary Proliferation in a Patient on Erlotinib.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The new molecular targeted therapy has been developed over the past decades by using the molecular targeted molecular changes discovered in specific types of cancer. Unfortunately, most of these agents (epidermal growth factor receptors, multi-targeted small molecule tyrosine kinase inhibitors, monoclonal antibodies) have severe cutaneous adverse reactions, that not only interfere with the patient's quality of life, but also are dose-limiting and may require treatment interruptions. These cutaneous complications and their management must be very well known by any oncologist and dermatologist who treat oncologic patients. ABBREVIATIONS: EGFR = epidermal growth factor receptors, EGFRI = epidermal growth factor receptors inhibitors.
Indexed as
Identifiers
27974909PMC5152604W2565666679What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.